A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline

Croft, Harry A.; Settle, Edmund C.; Houser, Trisha L.; Batey, Sharyn R.; Donahue, Rafe; Ascher, John

doi:10.1016/s0149-2918(00)88317-4

Cited by 206 publications

(128 citation statements)

References 17 publications

Supporting

Mentioning

111

Contrasting

Unclassified

Order By: Relevance

“…In a double-blind, placebo-controlled study on sertraline and bupropion in major depressed patients [14], sertraline induced far higher sexual complaints than bupropion (52% versus 8%). This was also found in studies on sertraline versus bupropion [15], paroxetine versus bupropion [16], escitalopram versus bupropion [17], and venlafaxine (a noradrenaline/serotonin reuptake blocker-SNRI) versus bupropion [18]. Recently, new SSRIs with additional serotonergic mechanisms like vilazodone and vortioxetine were introduced.…”

Section: What Are the Sexual Side Effects Of Antidepressants In Men?mentioning

confidence: 68%

Sexual Dysfunction, Depression and Antidepressants: A Translational Approach

Olivier¹,

Franco²,

Waldinger³

et al. 2017

Sexual Dysfunction

View full text Add to dashboard Cite

Major depression is frequently associated with sexual dysfunctions. Most antidepressants, especially selective serotonin reuptake inhibitors (SSRIs), induce additional sexual side effects and, although effective antidepressants, deteriorate sexual symptoms, which are the main reason that patients stop antidepressant treatment. Many strategies have been used to circumvent the additional sexual side effects, but results are rather disappointing. Recently, new antidepressants have been introduced, vilazodone and vortioxetine, which seem to lack sexual side effects in the early registration trials. Much research with large numbers of depressed patients and adequate methodological tools still has to confirm in daily use the absence of sexual side effects of new antidepressants. Animal models that in an early phase of drug development may predict putative sexual side effects of new antidepressants are extremely useful and could speed up development of new antidepressants. A rat model of sexual behavior is described that has a very high predictive validity for sexual side effects in man. Several characteristics of present antidepressants with regard to sexual dysfunctions are also present in the rat model and establish its validity. The animal model can also be used in the search for new psychotropics without sexual side effects or for drugs with sexual stimulating activity.

show abstract

Section: What Are the Sexual Side Effects Of Antidepressants In Men?mentioning

confidence: 68%

Sexual Dysfunction, Depression and Antidepressants: A Translational Approach

Olivier¹,

Franco²,

Waldinger³

et al. 2017

Sexual Dysfunction

View full text Add to dashboard Cite

show abstract

“…A few systematic reviews addressed the issue of sexual dysfunction associated with SGAD in patients with MDD [10,[15][16][17][18][19]. With the exception of an updated meta-analysis by Gartlehner et al [11], which also included data from observational studies, previous systematic reviews focused on efficacy trials.…”

Section: Introductionmentioning

confidence: 99%

Sexual Dysfunction associated with Second-Generation Antidepressants in Patients with Major Depressive Disorder: Results from a Systematic Review with Network Meta-Analysis

et al. 2013

View full text Add to dashboard Cite

BACKGROUND: Sexual dysfunction (SD) is prevalent in patients with major depressive disorder (MDD) and is also associated with second-generation antidepressants (SGAD) which are commonly used to treat the condition. Evidence indicates underreporting of SD in efficacy studies. SD associated with antidepressant treatment is a serious side effect that may lead to early termination of treatment and worsening of quality of life. OBJECTIVES: To systematically assess the harms of SD associated with SGAD in adult patients with MDD by drug type. METHODS: We retrieved English-language abstracts from PubMed, EMBASE, the Cochrane Library, PsycINFO, and International Pharmaceutical Abstracts from 1980 to October 2012 as well as from reference lists of pertinent review articles and grey literature searches. Two independent reviewers identified randomized controlled trials (RCTs) of at least six weeks' duration and observational studies with at least 1,000 participants. STUDY SELECTION: Reviewers abstracted data on study design, conduct, participants, interventions, outcomes and method of SD ascertainment, and rated risk of bias. A senior reviewer checked and confirmed extracted data and risk of bias ratings. ANALYSES: Random effects network meta-analysis using Bayesian methods for data from head-to-head trials and placebo-controlled comparisons; descriptive analyses calculating weighted mean rates from individual trials and observational studies. RESULTS/ SYNTHESIS: Data from sixty-three studies of low and moderate risk of bias (58 RCTs, five observational studies) with more than 26,000 patients treated with SGAD were included. Based on network meta-analyses of 66 pairwise comparisons from 37 RCTs, most comparisons showed a similar risk of sexual dysfunction among included SGAD. Credible intervals, however, were wide and included differences that would be considered clinically relevant. We observed three main patterns: Bupropion had a statistically significantly lower risk of sexual dysfunction than some other SGAD, and both escitalopram, and paroxetine showed a statistically significantly higher risk of sexual dysfunction than some other SGAD. We found reporting of harms related to sexual dysfunction inconsistent and insufficient in some trials. LIMITATIONS: Most trials were conducted in highly selected populations. Search was restricted to English-language only. CONCLUSION AND IMPLICATIONS: Because of the indirect nature of the comparisons, the often wide credible intervals, and the high variation in magnitude of 2 outcome, we rated the overall strength of evidence with respect to our findings low. The current degree of evidence does not allow a precise estimate of comparative risk of sexual dysfunction associated with a specific antidepressant. In the absence of such evidence, clinicians need to be aware of SD as a common adverse event and should discuss patients' preferences before initiating antidepressant therapy.

show abstract

“…Bupropion hydrochloride sustained release (SR) and sertraline have demonstrated antidepressant efficacy in randomized, double-blind, placebo-controlled studies in outpatients with major depressive disorder (Reimherr et al 1990(Reimherr et al , 1998Fabre et al 1995;Croft et al 1999;Coleman et al 1999). Bupropion has demonstrated comparable antidepressant efficacy to sertraline (Kavoussi et al 1997;Croft et al 1999;Coleman et al 1999), fluoxetine (Feighner et al 1991), and paroxetine (Weihs et al 2000) in outpatients with major depressive disorder.…”

mentioning

confidence: 99%

“…Bupropion has demonstrated comparable antidepressant efficacy to sertraline (Kavoussi et al 1997;Croft et al 1999;Coleman et al 1999), fluoxetine (Feighner et al 1991), and paroxetine (Weihs et al 2000) in outpatients with major depressive disorder. Compared with other antidepressants, bupropion SR is among the least sedating ones (American Psychiatric Association 1993).…”

mentioning

confidence: 99%

Response in Relation to Baseline Anxiety Levels in Major Depressive Disorder Treated with Bupropion Sustained Release or Sertraline

Rush

2001

Neuropsychopharmacology

View full text Add to dashboard Cite

A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline

Cited by 206 publications

References 17 publications

Sexual Dysfunction, Depression and Antidepressants: A Translational Approach

Sexual Dysfunction, Depression and Antidepressants: A Translational Approach

Sexual Dysfunction associated with Second-Generation Antidepressants in Patients with Major Depressive Disorder: Results from a Systematic Review with Network Meta-Analysis

Response in Relation to Baseline Anxiety Levels in Major Depressive Disorder Treated with Bupropion Sustained Release or Sertraline

Contact Info

Product

Resources

About